Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5FCP1
|
|||
| Drug Name |
TTI-622
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-10: C81-C86; ICD-9: 202] | Phase 1 | [1] | |
| Myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1 | [1] | ||
| Company |
Trillium Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen CD47 (CD47) | Target Info | Blocker | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03530683) A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma (TTI-622-01). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Trillium Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.